![]() | |
Names | |
---|---|
Preferred IUPAC name N-(2-Hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.164.363 |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C7H10N4O4 | |
Molar mass | 214.181 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Etanidazole is a nitroimidazole drug that was investigated in clinical trials for its radiosensitizing properties in cancer treatment. Administration of etanidazole results in a decrease of glutathione concentration and inhibits glutathione S-transferase. [1] [2] The result is that tissues become more sensitive to the ionizing radiation. [3]